These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30592022)

  • 21. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
    Wang XL; Li AM
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
    Meyer O; Wong RSM; Khelif A; Stankovic M; Maier J; Saleh MN; Bussel JB
    Br J Haematol; 2022 Jan; 196(2):448-452. PubMed ID: 34458977
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
    González-López TJ; Sánchez-González B; Jarque I; Bernat S; Fernández-Fuertes F; Caparrós I; Soto I; Fernández-Rodríguez A; Bolaños E; Pérez-Rus G; Pascual C; Hernández-Rivas JA; López-Ansoar E; Gómez-Nuñez M; Martínez-Robles V; Olivera P; Yera Cobo M; Peñarrubia MJ; Fernández-Miñano C; de Cabo E; Martínez Badas MP; Perdomo G; García-Frade LJ
    Eur J Haematol; 2020 Mar; 104(3):259-270. PubMed ID: 31840311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
    Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G
    Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
    Poston JN; Gernsheimer TB
    Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.
    Elgebaly AS; Ashal GE; Elfil M; Menshawy A
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):928-937. PubMed ID: 27572890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
    Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients.
    Mei H; Xu M; Yuan G; Zhu F; Guo J; Huang R; Qin J; Lv T; Qin F; Cai H; Yin P; Qin T; Hu Y
    Br J Haematol; 2021 Dec; 195(5):781-789. PubMed ID: 34528239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
    Grainger JD; Thind S
    Pediatr Hematol Oncol; 2017 Mar; 34(2):73-89. PubMed ID: 28537785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
    Boyers D; Jia X; Jenkinson D; Mowatt G
    Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.